<DOC>
	<DOCNO>NCT02517021</DOCNO>
	<brief_summary>NEPA-15-18 clinical study assess safety pro-netupitant palonosetron , two antiemetic drug , give oral dexamethasone . The objective study evaluate pro-netupitant palonosetron safe administer prevent nausea vomit administration repeat cycle chemotherapy .</brief_summary>
	<brief_title>A Safety Study Intravenous Pro-Netupitant Palonosetron Combination Prevention Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>Cycle 1 Signed write informed consent Histologically cytologically confirm solid tumor malignancy . Naïve cytotoxic chemotherapy . Previous biological hormonal therapy permit . Scheduled receive least 4 repeated consecutive cycle follow highly emetogenic reference chemotherapy ( HEC ) , alone combination chemotherapeutic agent Day 1 : cisplatin administer single IV dose ≥ 70 mg/m2 ; cyclophosphamide ≥1500 mg/m2 ; carmustine ( BCNU ) &gt; 250mg/m2 ; dacarbazine ( DTIC ) ; mechloretamine ( nitrogen mustard ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 . If patient female , shall nonchildbearing potential childbearing potential use reliable contraceptive measure negative urine pregnancy test . Hematologic metabolic status adequate receiving highly emetogenic regimen base laboratory criterion ( Total Neutrophils , Platelets , Bilirubin , Liver enzymes , Serum Creatinine Creatinine Clearance ) Able read , understand , follow study procedure complete patient diary . Cycles 2 4 : The follow inclusion criterion must check prior inclusion repeat cycle : Participation study next cycle chemotherapy consider appropriate Investigator pose unwarranted risk patient . Scheduled receive chemotherapy regimen Cycle 1 one reference chemotherapy define Inclusion criterion 5 Cycle 1 . If patient female , shall nonchildbearing potential childbearing potential use reliable contraceptive measure negative urine pregnancy test . Adequate hematologic metabolic status accord Investigator 's opinion . Cycle 1 Lactating woman . Active infection uncontrolled disease except malignancy may pose unwarranted risk administer study drug patient . Current use illicit drug current evidence alcohol abuse . Scheduled receive moderately highly emetogenic chemotherapy Day 2 Day 5 . Received scheduled receive radiation therapy abdomen pelvis within 1 week prior start reference chemotherapy administration Day 1 Days 1 5 . Any vomiting , retch , nausea ( grade ≥ 1 defined National Cancer Institute ) within 24 hour prior start reference chemotherapy administration Day 1 . Symptomatic primary metastatic CNS malignancy . Known hypersensitivity contraindication 5HT3 receptor antagonist , dexamethasone NK1 receptor antagonist . Known contraindication IV administration 50 mL 5 % glucose solution . Previously receive NK1 receptor antagonist . Participation previous clinical trial involve IV pronetupitant oral netupitant administer alone combination palonosetron . Any investigational drug ( give study ) take within 4 week prior Day 1 , and/or schedule receive investigational drug present study . Systemic corticosteroid therapy dose within 72 hour prior start reference chemotherapy administration Day 1 . Topical inhale corticosteroid permit . Scheduled receive bone marrow transplantation and/or stem cell rescue therapy . Scheduled receive strong moderate inhibitor CYP3A4 intake within 1 week prior Day 1 . Scheduled receive follow CYP3A4 substrate within 1 week prior Day 1 : terfenadine , cisapride , astemizole , pimozide . Received within 4 week prior Day 1 schedule receive CYP3A4 inducer . Any medication know potential antiemetic activity within 24 hour prior start reference chemotherapy administration Day 1 Cycle 1 , include limited 5HT3 receptor antagonist NK1 receptor antagonists History predisposition cardiac conduction abnormality , except incomplete right bundle branch block History Torsade de Point know history risk factor Torsade de Point ( heart failure , hypokalemia , family history Long QT Syndrome ) . Severe cardiovascular disease diagnose within 3 month prior Day 1 first cycle , include myocardial infarction , unstable angina pectoris , significant valvular pericardial disease , history ventricular tachycardia , symptomatic Congestive Heart Failure ( CHF ) New York Heart Association ( NYHA ) class IIIIV , severe uncontrolled arterial hypertension . Any illness condition , opinion Investigator , may confound result study pose unwarranted risk administer investigational product patient . Concurrent medical condition would preclude administration dexamethasone systemic fungal infection uncontrolled diabetes . Cycles 2 4 : The follow exclusion criterion must check prior inclusion repeat cycle : Lactating woman . Active infection uncontrolled disease except malignancy may pose unwarranted risk administer study drug patient . Started restricted medication . Any vomiting , retch , nausea ( grade ≥ 1 defined National Cancer Institute ) within 24 hour prior start reference chemotherapy administration Day 1 . Received scheduled receive radiation therapy abdomen pelvis within 1 week prior start reference chemotherapy administration Day 1 Days 1 5 . Symptomatic primary metastatic CNS malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>